Embryonic stem cell-derived cardiac myocytes are not ready for human trials

Mark Anderson, Joshua Goldhaber, Steven R. Houser, Michel Puceat, Mark A. Sussman

Research output: Contribution to journalArticle

Abstract

Recently, a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a nonhuman primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalCirculation Research
Volume115
Issue number3
DOIs
StatePublished - Jul 18 2014
Externally publishedYes

Fingerprint

Embryonic Stem Cells
Cardiac Myocytes
Primates
Myocardium
Clinical Trials
Safety
Human Embryonic Stem Cells

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Embryonic stem cell-derived cardiac myocytes are not ready for human trials. / Anderson, Mark; Goldhaber, Joshua; Houser, Steven R.; Puceat, Michel; Sussman, Mark A.

In: Circulation Research, Vol. 115, No. 3, 18.07.2014, p. 335-338.

Research output: Contribution to journalArticle

Anderson, Mark ; Goldhaber, Joshua ; Houser, Steven R. ; Puceat, Michel ; Sussman, Mark A. / Embryonic stem cell-derived cardiac myocytes are not ready for human trials. In: Circulation Research. 2014 ; Vol. 115, No. 3. pp. 335-338.
@article{37e7ca51b8844ece8f521bfdd24203dd,
title = "Embryonic stem cell-derived cardiac myocytes are not ready for human trials",
abstract = "Recently, a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a nonhuman primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.",
author = "Mark Anderson and Joshua Goldhaber and Houser, {Steven R.} and Michel Puceat and Sussman, {Mark A.}",
year = "2014",
month = "7",
day = "18",
doi = "10.1161/CIRCRESAHA.114.304616",
language = "English (US)",
volume = "115",
pages = "335--338",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Embryonic stem cell-derived cardiac myocytes are not ready for human trials

AU - Anderson, Mark

AU - Goldhaber, Joshua

AU - Houser, Steven R.

AU - Puceat, Michel

AU - Sussman, Mark A.

PY - 2014/7/18

Y1 - 2014/7/18

N2 - Recently, a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a nonhuman primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.

AB - Recently, a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a nonhuman primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84904596460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904596460&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.114.304616

DO - 10.1161/CIRCRESAHA.114.304616

M3 - Article

C2 - 24935962

AN - SCOPUS:84904596460

VL - 115

SP - 335

EP - 338

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 3

ER -